Skip to content
drillr.ai
Sign up

JANX

Janux Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$16.59
−1.60%
Ask drillr

  • Sep 14, 2026, 12:00 UTC

    Janux Therapeutics dosed the first patient in a Phase 1 clinical trial of JANX013, a PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer.

    Source:

  • Aug 6, 2026, 22:21 UTC

    Janux Therapeutics reported a second-quarter net loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, and compared to a $0.55 loss per share in the same quarter last year.

    Source: